News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
378,935 Results
Type
Article (33103)
Company Profile (67)
Press Release (345765)
Section
Business (102348)
Career Advice (2548)
Deals (18495)
Drug Delivery (90)
Drug Development (50095)
Employer Resources (152)
FDA (9399)
Job Trends (9573)
News (184009)
Policy (19420)
Tag
Academia (2096)
Alliances (25568)
Alzheimer's disease (898)
Approvals (9375)
Artificial intelligence (99)
Bankruptcy (127)
Best Places to Work (7826)
Breast cancer (142)
Cancer (954)
Cardiovascular disease (80)
Career advice (2142)
CAR-T (80)
Cell therapy (205)
Clinical research (39900)
Collaboration (286)
Compensation (157)
COVID-19 (2073)
Data (983)
Diabetes (132)
Diagnostics (3671)
Drug pricing (74)
Earnings (47114)
Employer resources (133)
Events (57498)
Executive appointments (177)
FDA (9838)
Funding (231)
Gene therapy (168)
GLP-1 (446)
Government (3325)
Healthcare (12174)
Infectious disease (2137)
Interviews (459)
IPO (9220)
Job creations (2075)
Job search strategy (1772)
Layoffs (318)
Legal (4207)
Lung cancer (149)
Lymphoma (79)
Manufacturing (138)
Medical device (7552)
Medtech (7553)
Mergers & acquisitions (9434)
Metabolic disorders (358)
Neuroscience (1134)
NextGen Class of 2024 (4320)
Non-profit (3352)
Northern California (996)
Obesity (197)
Opinion (208)
Parkinson's disease (74)
Patents (71)
People (21764)
Phase I (11405)
Phase II (17344)
Phase III (14766)
Pipeline (350)
Postmarket research (1692)
Preclinical (4778)
Radiopharmaceuticals (119)
Rare diseases (205)
Real estate (3164)
Regulatory (12923)
Research institute (1734)
Resumes & cover letters (429)
Southern California (878)
Startups (1942)
United States (8936)
Vaccines (457)
Weight loss (154)
Date
Last 7 days (101)
Last 30 days (985)
Last 365 days (20775)
2025 (58)
2024 (21127)
2023 (23712)
2022 (30573)
2021 (34411)
2020 (33024)
2019 (29325)
2018 (22557)
2017 (18893)
2016 (18895)
2015 (21432)
2014 (15556)
2013 (12830)
2012 (13513)
2011 (14252)
2010 (12202)
Location
Africa (642)
Arizona (96)
Asia (22892)
Australia (3886)
California (2230)
Canada (922)
China (196)
Colorado (104)
Connecticut (108)
Europe (52365)
Florida (335)
Georgia (80)
Illinois (253)
Indiana (149)
Maryland (372)
Massachusetts (1661)
Michigan (93)
Minnesota (145)
New Jersey (721)
New York (691)
North Carolina (468)
Northern California (996)
Ohio (75)
Pennsylvania (551)
South America (906)
Southern California (878)
Texas (306)
Utah (73)
Washington State (200)
378,935 Results for "one drop".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BIOSECURE Act
WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms
With the BIOSECURE Act likely to be voted on in Congress this year, WuXi AppTec’s U.S. revenue dropped 1.2% in the first half of 2024 while the Chinese company increased its lobbying efforts.
July 29, 2024
·
2 min read
·
Tyler Patchen
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Business
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical.
December 17, 2024
·
3 min read
·
Kate Goodwin
Business
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.
November 13, 2024
·
7 min read
·
Annalee Armstrong
Press Releases
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
December 24, 2024
·
4 min read
Drug Development
Eyenovia Shares Plummet 70% After It Drops Lead Program
Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.
November 15, 2024
·
2 min read
·
Heather McKenzie
Policy
GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit
On Monday, GSK reported that a plaintiff voluntarily dropped her Zantac case against the company and that it is in the process of appealing a Delaware State Court’s decision to admit expert testimony in other cases.
June 11, 2024
·
2 min read
·
Tristan Manalac
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
·
2 min read
·
Tristan Manalac
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Layoffs
23andMe Cuts Headcount by 40%, Drops Drug Discovery Work
In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including licensing deals or outright sales.
November 12, 2024
·
2 min read
·
Tristan Manalac
1 of 37,894
Next
